Lim et al. [10] showed in a retrospective study that KTRs with T2DM who had been treated with SGLT2 inhibitors had a better prognosis with respect to all-cause mortality, death-censored graft failure and doubling of serum creatinine compared with KTRs with T2DM not treated with SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.